HBMN:SWX
HBM Healthcare Investments AG
CHF 226.50
arrow_downward
-0.44%(-1.00) 1D
Oct 23, 4:30:11 PM GMT+1 · CHF
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HBMN...
Open
CHF 230.00
High
CHF 230.00
Low
CHF 226.00
Mkt. cap
1.50B
Avg. vol.
4.71K
Volume
3.70K
Dividend
3.97%
Quarterly dividend
CHF 2.25
Ex-dividend date
Jun 17, 2026
P/E ratio
2.32
52-wk high
CHF 258.00
52-wk low
CHF 193.00
EPS
CHF 97.76
Shares outstanding
6.62M
Open
CHF 230.00
High
CHF 230.00
Low
CHF 226.00
Mkt. cap
1.50B
Avg. vol.
4.71K
Volume
3.70K
Dividend
3.97%
Quarterly dividend
CHF 2.25
Ex-dividend date
Jun 17, 2026
P/E ratio
2.32
52-wk high
CHF 258.00
52-wk low
CHF 193.00
EPS
CHF 97.76
Shares outstanding
6.62M
News stories
From web sources and news partners
MarketWatch
·
11 minutes ago
Worried about this stock-market selloff? Relief may be coming after the midterms — no matter who wins.
FXEmpire
·
23 minutes ago
S&P500: AI Spending, Big Tech Earnings and Fed Risk Test US Stock Market
Profile
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
About HBM Healthcare Investments AG
CEO-
Employees-
FoundedJul 12, 2001
HeadquartersZug, Zug, Switzerland
SectorCapital market
Websitehbmhealthcare.com